Financing the discovery of brand new plant-based drugs that could help
improve the lives of many people around the world.
Funding R&D companies to research the pharmacology of cannabinoids which continues to yield highly promising data and new IP across a range of therapeutic areas
Backing global-leading cannabinoid scientists which continue to explore the potential of a range of novel cannabinoid molecules in a number of distinct therapeutic areas including epilepsy, glioma, and schizophrenia
Managed by a team of proven entrepreneurs and businessmen that have a good understanding of this market
Funding R&D companies to research the pharmacology of cannabinoids which continues to yield highly promising data and new IP across a range of therapeutic areas
Backing global-leading cannabinoid scientists which continue to explore the potential of a range of novel cannabinoid molecules in a number of distinct therapeutic areas including epilepsy, glioma, and schizophrenia
Managed by a team of proven entrepreneurs and businessmen that have a good understanding of this market
Financing the discovery of brand new plant-based
drugs that could help improve the lives of many
people around the world.
In-depth market research to identify potential investee companies with compelling R&D in medical cannabis
Extensive face to face meetings with potential investee companies
Due diligence and painstaking analysis of technology and business model
Advance funds as direct investment or loans against achieving pre-agreed milestones
Work with management teams to create value
Appointment of key advisers and able to nominate a Non-Executive Director to the board
Exits will be sought by way of share buy-back, listing on a recognised stock exchange, acquisition by an industrial buyer, merger with another organisation etc.
Quickly being legalised in growing number of countries: Argentina, Brazil, Canada,
Chile, Colombia, Czech, Germany, Italy, Mexico, Spain, UK, USA and Uruguay.
Global medical cannabis market was
worth US$16.5 billion in 2019¹
22.8% compound annual growth rate (CAGR) forecast over the 2020-25 period¹
Market forecast to be worth
US$58.5 billion by 2025¹
More rapid growth is forecast for this sub-sector of the medical cannabis market¹
Global CBD market valued at
US$553.7 million in 2020
by the end of 2026 growing at a CAGR
of 33.5% during 2021-26²
forecast to reach US$4,268.3 million
by the end of 2026
CBD wellness is an expanding category with CBD incorporated into edibles as well as being infused
into cosmetics and pet products. Industry clamouring for CBD to listed as “generally recognised as
safe” and so it is classified in the same way as vanilla flavouring and caffeine.
Medical cannabis is any cannabis-based medicine that relieves symptoms.
Cannabis has been used medicinally for more than 4,500 years.
In 2,727BC, Emperor Shen-Nung recognised its treatment properties in over 100 ailments including rheumatism and gout. Napoleon returned from Egypt in 1798 with cannabis which was investigated for pain relief and sedation. Elsewhere at that time, cannabis was being used to treat tumours, coughs and jaundice.
In the early 20th century cannabis use fell out of favour with
regulators and the culture of the western world.
Trend led by Canada which changed it laws in 2001 to legalise the medicinal use of cannabis
Growing number of countries legalising cannabis for medical use
UK regulations changed in November 2018 following public pressure
Today the NHS prescribes medicinal cannabis for severe forms of epilepsy, nausea caused by chemotherapy and muscle stiffness/ spasms caused by MS
Medical cannabis is still in its introductory phase in the healthcare industry
Substantial growth is predicted for medical cannabis
Financing the discovery of brand new plant-based drugs that could help
improve the lives of many people around the world.
